Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 687-691

  Jiang, Jingting ^a   Wu, Changping ^a   Shen, Yueping ^a   Xu, Bin ^a   Zheng, Xiao ^a   Li, Xiaodong ^a   Xu, Ning ^b  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

AFP IgM immune complexes; Alpha fetoprotein; Biomarker; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCHEMICAL ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUMINESCENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIGEN-ANTIBODY COMPLEX; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN M; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79953237655     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Herszenyi L and Tulassay Z: Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 14: 249-258, 2010.
2. Nissen NN and Martin P: Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 35: S79-85, 2002.
3. Zhiqiang G, Zhaohui D, Qinhuan W, Dexian C, Yunyun F, Hongtao L and Iloeje UH: Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 38: S175-178, 2004.
4. Shi J, Zhu L, Liu S and Xie WF: A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 92: 607-612, 2005. (Pubitemid 40395547)
5. Jiang J, Zhang X, Wu C, Qin X, Luo G, Lu M, Deng H, Li M, Xu B, Ji M and Xu N: Alterations of plasma apolipoprotein M and other lipid profile patterns in the hepatocellular carcinoma patients. Lipids in Health and Disease 7: 25, 2008.
6. Jiang JT, Wu CP, Xu N and Zhang XG: Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 8: 25-28, 2009.
7. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Umoine A, Bismuth H, Castaing D and Adam R: Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 10: 129-137, 2010.
8. Shu H, Kang X, Guo K, Li S, Li M, Sun L, Gan L, Liu Y and Qin X: Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to alpha fetoprotein. Oncol Rep 24: 1271-1276, 2010.
9. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S and Montalto G: Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 23: 1747-1753, 2003. (Pubitemid 36750842)
10. Tong MJ, Blatt LM and Kao VW: Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 16: 553-559, 2001. (Pubitemid 34188864)
11. Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P and Fassina G: Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers 19: 155-159, 2004. (Pubitemid 39106942)
12. Jingting J, Changping W, Ning X, Yibei Z, Jun W, Mei J, Bin X, Peter NE and Xueguan Z: Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma. J Clin Lab Anal 23: 213-218, 2009.
13. Sheng SL, Wang Q, Huang G, Yu B and Qin WX: Simultaneous determination of alpha-fetoprotein immune complexes and alpha-fetoprotein concentration in hepatocellular carcinoma using dual-label time-resolved immunofluorometric assays. J Clin Lab Anal 23: 179-185, 2009.
14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M and Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430, 2001. (Pubitemid 32844200)
15. Sobin LH and Wittekind C (eds): TNM Classification of Malignant Tumours (6th edited). UICC (International Union Against Cancer). New York: Wiley-Liss 81: 65-68, 2002.
16. Hanley JA and McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843, 1983. (Pubitemid 13033817)
17. Jiang J, Nilsson-Ehle P and Xu N: Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5(4): 1-7, 2006.
18. Jiang JT, Xu N, Zhang XY and Wu CP: Lipids changes in liver cancer. J Zhejiang Univ Sci B 8: 398-409, 2007.
19. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A and Malaguarnera M: Serum markers of hepatocellular carcinoma. Dig Dis Sci 55: 2744-2755, 2010.
20. Achenbach T, Seifert JK, Pitton MB, Schunk K and Junginger T: Chemoembolization for primary liver cancer. Eur J Surg Oncol 28: 37-41, 2002. (Pubitemid 41122780)